
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen is showing strong growth in both its biopharma services and diagnostic testing products, with revenue growth of 12% year over year. The company is also expanding its sales force and launching new products, positioning it for continued growth in the future. Despite facing some headwinds in the market, Exagen's positive outlook and strategic initiatives make it an attractive investment opportunity for long-term growth.
Bears say
Exagen is showing positive growth in their sales territories, with their average revenue per sales rep increasing from $285k to $430k over the past two years. With an expansion to 45 sales territories and changes in the commercial team leadership, the company is well-positioned to continue this growth. The long-term outlook for Exagen includes achieving gross margins in the mid-60s and an average selling price of $525 per test.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares